Literature DB >> 23727259

Human stem cell-based three-dimensional microtissues for advanced cardiac cell therapies.

Maximilian Y Emmert1, Petra Wolint, Nadine Wickboldt, Gino Gemayel, Benedikt Weber, Chad E Brokopp, Alessandro Boni, Volkmar Falk, Alexis Bosman, Marisa E Jaconi, Simon P Hoerstrup.   

Abstract

Cardiac stem cell therapy has been proposed as a therapy option to treat the diseased myocardium. However, the low retention rate of transplanted single-cell suspensions remains a major issue of current therapy strategies. Therefore, the concept of scaffold-free cellular self-assembly into three-dimensional microtissues (3D-MTs) prior to transplantation may be beneficial to enhance retention and survival. We compared clinically relevant, human stem cell sources for their ability to generate 3D-MTs with particular regards to formation characteristics, proliferation-activity, viability and extracellular-matrix production. Single-cell suspensions of human bone marrow- and adipose tissue-derived mesenchymal stem cells (hBMMSCs and hATMSCs), Isl1(+) cardiac progenitors derived from human embryonic stem cells (hESC-Isl1(+) cells), and undifferentiated human induced pluripotent cells (hiPSCs) were characterized before to generate 3D-MTs using a hanging-drop culture. Besides the principal feasibility of cell-specific 3D-MT formation, a detailed head-to-head comparison between cell sources was performed using histology, immunocyto- and histo-chemistry as well as flow cytometry. Round-oval shaped and uniform 3D-MTs could be successfully generated from all cell types starting with a loose formation within the first 24 h that fully stabilized after 3 days and resulting in a mean 3D-MT diameter of 194.56 ± 18.01 μm (hBMMSCs), 194.56 ± 16.30 μm (hATMSCs), 159.73 ± 19.20 μm (hESC-Isl1(+) cells) and 120.95 ± 7.97 μm (hiPSCs). While all 3D-MTs showed a homogenous cell distribution, hiPSC-derived 3D-MTs displayed a compact cell formation primarily located at the outer margin. hESC-Isl1(+) and hiPSC-derived 3D-MTs maintained their proliferation-activity which was rather limited in the MSC-based 3D-MTs. All four 3D-MT types revealed a comparable viability in excess of 70% and showed a cell-specific expression profile being comparable to their single-cell counterparts. Extracellular matrix (ECM) production during 3D-MT formation was observed for all cell-specific 3D-MTs, with hiPSC-derived 3D-MTs being the fastest one. Interestingly, ECM distribution was homogenous for hATMSC- and hiPSC-based 3D-MTs, while it appeared to be primarily concentrated within in the center of hESC-Isl1(+) and hBMMSC-based 3D-MTs. The results of this head-to-head comparative study indicated that 3D-MTs can be successfully generated from hESC-derived Isl1(+) cells, hiPSCs and MSC lines upon hanging drop culture. Cell-specific 3D-MTs displayed sufficient viability and instant ECM formation. The concept of 3D-MT in vitro generation prior to cell transplantation may represent a promising delivery format for future strategies to enhance cellular engraftment and survival.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23727259     DOI: 10.1016/j.biomaterials.2013.04.034

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  25 in total

Review 1.  Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties, and applications.

Authors:  Sébastien Sart; Ang-Chen Tsai; Yan Li; Teng Ma
Journal:  Tissue Eng Part B Rev       Date:  2013-12-13       Impact factor: 6.389

2.  Phenotypic Variation Between Stromal Cells Differentially Impacts Engineered Cardiac Tissue Function.

Authors:  Tracy A Hookway; Oriane B Matthys; Federico N Mendoza-Camacho; Sarah Rains; Jessica E Sepulveda; David A Joy; Todd C McDevitt
Journal:  Tissue Eng Part A       Date:  2019-05       Impact factor: 3.845

Review 3.  Three-dimensional scaffold-free microtissues engineered for cardiac repair.

Authors:  Alejandra Patino-Guerrero; Jaimeson Veldhuizen; Wuqiang Zhu; Raymond Q Migrino; Mehdi Nikkhah
Journal:  J Mater Chem B       Date:  2020-07-29       Impact factor: 6.331

Review 4.  Cardiac Regenerative Medicine: The Potential of a New Generation of Stem Cells.

Authors:  Elena Cambria; Julia Steiger; Julia Günter; Annina Bopp; Petra Wolint; Simon P Hoerstrup; Maximilian Y Emmert
Journal:  Transfus Med Hemother       Date:  2016-07-26       Impact factor: 3.747

Review 5.  Cardiovascular Regenerative Technologies: Update and Future Outlook.

Authors:  Anna Mallone; Benedikt Weber; Simon P Hoerstrup
Journal:  Transfus Med Hemother       Date:  2016-07-21       Impact factor: 3.747

Review 6.  3D bioprinting for cardiovascular regeneration and pharmacology.

Authors:  Haitao Cui; Shida Miao; Timothy Esworthy; Xuan Zhou; Se-Jun Lee; Chengyu Liu; Zu-Xi Yu; John P Fisher; Muhammad Mohiuddin; Lijie Grace Zhang
Journal:  Adv Drug Deliv Rev       Date:  2018-07-24       Impact factor: 15.470

7.  Microscale generation of cardiospheres promotes robust enrichment of cardiomyocytes derived from human pluripotent stem cells.

Authors:  Doan C Nguyen; Tracy A Hookway; Qingling Wu; Rajneesh Jha; Marcela K Preininger; Xuemin Chen; Charles A Easley; Paul Spearman; Shriprasad R Deshpande; Kevin Maher; Mary B Wagner; Todd C McDevitt; Chunhui Xu
Journal:  Stem Cell Reports       Date:  2014-07-04       Impact factor: 7.765

Review 8.  Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease.

Authors:  Alexis Bosman; Michael J Edel; Gillian Blue; Rodney J Dilley; Richard P Harvey; David S Winlaw
Journal:  J Clin Med       Date:  2015-04-22       Impact factor: 4.241

Review 9.  Bioprocessing strategies for the large-scale production of human mesenchymal stem cells: a review.

Authors:  Krishna M Panchalingam; Sunghoon Jung; Lawrence Rosenberg; Leo A Behie
Journal:  Stem Cell Res Ther       Date:  2015-11-23       Impact factor: 6.832

Review 10.  Microtissues in Cardiovascular Medicine: Regenerative Potential Based on a 3D Microenvironment.

Authors:  Julia Günter; Petra Wolint; Annina Bopp; Julia Steiger; Elena Cambria; Simon P Hoerstrup; Maximilian Y Emmert
Journal:  Stem Cells Int       Date:  2016-03-17       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.